Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
FDF
0
Weekly News Recap #Phispers
1. Gsk2140944
1. 1075236-89-3
2. Gsk2140944
3. Gsk-2140944
4. Gsk 2140944
5. Dvf0pr037d
6. 3h,8h-2a,5,8a-triazaacenaphthylene-3,8-dione, 2-((4-(((3,4-dihydro-2h-pyrano(2,3-c)pyridin-6-yl)methyl)amino)-1-piperidinyl)methyl)-1,2-dihydro-, (2r)-
7. (2r)-2-[(4-{[(3,4-dihydro-2h-pyrano[2,3-c]pyridin- 6-yl)methyl]amino}piperidin-1-yl)methyl]-1,2-dihydro- 3h,8h-2a,5,8a-triazaacenaphthylene-3,8-dione
8. (3~{r})-3-[[4-(3,4-dihydro-2~{h}-pyrano[2,3-c]pyridin-6-ylmethylamino)piperidin-1-yl]methyl]-1,4,7-triazatricyclo[6.3.1.0^{4,12}]dodeca-6,8(12),9-triene-5,11-dione
9. (3r)-3-[[4-(3,4-dihydro-2h-pyrano[2,3-c]pyridin-6-ylmethylamino)piperidin-1-yl]methyl]-1,4,7-triazatricyclo[6.3.1.04,12]dodeca-6,8(12),9-triene-5,11-dione
10. Gepotidacin [usan:inn]
11. Unii-dvf0pr037d
12. 3h,8h-2a,5,8a-triazaacenaphthylene-3,8-dione, 2-[[4-[[(3,4-dihydro-2h-pyrano[2,3-c]pyridin-6-yl)methyl]amino]-1-piperidinyl]methyl]-1,2-dihydro-, (2r)-
13. Jhn
14. Gepotidacin [inn]
15. Gepotidacin (usan/inn)
16. Gepotidacin [usan]
17. Gepotidacin [who-dd]
18. Schembl3332319
19. Chembl3317856
20. Gtpl10817
21. Dtxsid501028208
22. Bdbm50050549
23. Gsk 2140944e
24. Cs-6531
25. Db12134
26. Hy-16742
27. D10878
28. A857306
29. Q19597285
Molecular Weight | 448.5 g/mol |
---|---|
Molecular Formula | C24H28N6O3 |
XLogP3 | 0.1 |
Hydrogen Bond Donor Count | 1 |
Hydrogen Bond Acceptor Count | 7 |
Rotatable Bond Count | 5 |
Exact Mass | 448.22228878 g/mol |
Monoisotopic Mass | 448.22228878 g/mol |
Topological Polar Surface Area | 90.4 Ų |
Heavy Atom Count | 33 |
Formal Charge | 0 |
Complexity | 893 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 1 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Treatment of uncomplicated urogenital gonorrhea
Treatment of uncomplicated urinary tract infections
Topoisomerase Inhibitors
Compounds that inhibit the activity of DNA TOPOISOMERASES. (See all compounds classified as Topoisomerase Inhibitors.)
About the Company : Viyash, true to its name, literally represents honesty and leadership in every sense. We are an integrated pharmaceutical company with a strong portfolio of niche formulations, ...
Details:
Blujepa (gepotidacin) is the first in a new class of oral antibiotics which inhibits topoisomerase II/IV. It is approved for the treatment of uncomplicated urinary tract infections.
Lead Product(s): Gepotidacin,Inapplicable
Therapeutic Area: Infections and Infectious Diseases Brand Name: Blujepa
Study Phase: Approved FDFProduct Type: Antibiotic
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 25, 2025
Lead Product(s) : Gepotidacin,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Blujepa (Gepotidacin) FDA-Approved for Uncomplicated Urinary Tract Infections
Details : Blujepa (gepotidacin) is the first in a new class of oral antibiotics which inhibits topoisomerase II/IV. It is approved for the treatment of uncomplicated urinary tract infections.
Product Name : Blujepa
Product Type : Antibiotic
Upfront Cash : Inapplicable
March 25, 2025
Details:
Gepotidacin is a Antibiotic drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Urinary Tract Infections.
Lead Product(s): Gepotidacin,Inapplicable
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Antibiotic
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 19, 2024
Lead Product(s) : Gepotidacin,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Gepotidacin is a Antibiotic drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Urinary Tract Infections.
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
September 19, 2024
Details:
GSK 2140944 (gepotidacin) is a potential first-in-class oral antibiotic which inhibits bacterial DNA replication, with a novel mechanism of action for uncomplicated urogenital gonorrhoea.
Lead Product(s): Gepotidacin,Inapplicable
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Antibiotic
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 17, 2024
Lead Product(s) : Gepotidacin,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
EAGLE-1 Phase III Data Show Gepotidacin As New Oral Treatment for Gonorrhoea
Details : GSK 2140944 (gepotidacin) is a potential first-in-class oral antibiotic which inhibits bacterial DNA replication, with a novel mechanism of action for uncomplicated urogenital gonorrhoea.
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
April 17, 2024
Details:
GSK 2140944 (gepotidacin) is an investigational bactericidal antibiotic inhibiting bacterial DNA replication by a novel mechanism, evaluated for treating uncomplicated urogenital gonorrhea.
Lead Product(s): Gepotidacin,Inapplicable
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Antibiotic
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 26, 2024
Lead Product(s) : Gepotidacin,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
GSK Reports Positive Results from EAGLE-1 Trial for Gepotidacin
Details : GSK 2140944 (gepotidacin) is an investigational bactericidal antibiotic inhibiting bacterial DNA replication by a novel mechanism, evaluated for treating uncomplicated urogenital gonorrhea.
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
February 26, 2024
Details:
GSK 2140944 (gepotidacin) is an investigational bactericidal that inhibits bacterial DNA replication by a novel mechanism of action and binding site and provides well-balanced inhibition of two different Type II topoisomerase enzymes.
Lead Product(s): Gepotidacin,Inapplicable
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Antibiotic
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 15, 2023
Lead Product(s) : Gepotidacin,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Gepotidacin’s Positive Phase III Data Shows Potential to Be the First in A New Class of Oral Ant...
Details : GSK 2140944 (gepotidacin) is an investigational bactericidal that inhibits bacterial DNA replication by a novel mechanism of action and binding site and provides well-balanced inhibition of two different Type II topoisomerase enzymes.
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
April 15, 2023
Details:
Gepotidacin is a Antibiotic drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Urinary Tract Infections.
Lead Product(s): Gepotidacin,Inapplicable
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Antibiotic
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 30, 2022
Lead Product(s) : Gepotidacin,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Gepotidacin is a Antibiotic drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Urinary Tract Infections.
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
November 30, 2022
Details:
The EAGLE-2 and EAGLE-3 trials met primary efficacy endpoint of combined clinical and microbiological resolution following treatment at the Test-Of-Cure visit for gepotidacin (GSK 2140944) v/s nitrofurantoin in patients with uUTI and a uropathogen sensitive to nitrofurantoin.
Lead Product(s): Gepotidacin,Inapplicable
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Antibiotic
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 03, 2022
Lead Product(s) : Gepotidacin,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The EAGLE-2 and EAGLE-3 trials met primary efficacy endpoint of combined clinical and microbiological resolution following treatment at the Test-Of-Cure visit for gepotidacin (GSK 2140944) v/s nitrofurantoin in patients with uUTI and a uropathogen sensit...
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
November 03, 2022
Details:
Gepotidacin is a Antibiotic drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Lead Product(s): Gepotidacin,Inapplicable
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Antibiotic
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 09, 2022
Lead Product(s) : Gepotidacin,Inapplicable
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Gepotidacin is a Antibiotic drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
March 09, 2022
Details:
Gepotidacin is a Antibiotic drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Bacterial Infections.
Lead Product(s): Gepotidacin,Cimetidine
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Antibiotic
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 30, 2020
Lead Product(s) : Gepotidacin,Cimetidine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Drug-drug Interaction Study of Gepotidacin
Details : Gepotidacin is a Antibiotic drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Bacterial Infections.
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
July 30, 2020
Details:
Gepotidacin is a Antibiotic drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Urinary Tract Infections.
Lead Product(s): Gepotidacin,Inapplicable
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Antibiotic
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 05, 2019
Lead Product(s) : Gepotidacin,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Gepotidacin is a Antibiotic drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Urinary Tract Infections.
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
December 05, 2019
Market Place
Reply
16 Sep 2025
Reply
03 May 2023
ABOUT THIS PAGE
96
PharmaCompass offers a list of Gepotidacin API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Gepotidacin manufacturer or Gepotidacin supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Gepotidacin manufacturer or Gepotidacin supplier.
PharmaCompass also assists you with knowing the Gepotidacin API Price utilized in the formulation of products. Gepotidacin API Price is not always fixed or binding as the Gepotidacin Price is obtained through a variety of data sources. The Gepotidacin Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Gepotidacin manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Gepotidacin, including repackagers and relabelers. The FDA regulates Gepotidacin manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Gepotidacin API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Gepotidacin manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Gepotidacin supplier is an individual or a company that provides Gepotidacin active pharmaceutical ingredient (API) or Gepotidacin finished formulations upon request. The Gepotidacin suppliers may include Gepotidacin API manufacturers, exporters, distributors and traders.
click here to find a list of Gepotidacin suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
Gepotidacin Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Gepotidacin GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Gepotidacin GMP manufacturer or Gepotidacin GMP API supplier for your needs.
A Gepotidacin CoA (Certificate of Analysis) is a formal document that attests to Gepotidacin's compliance with Gepotidacin specifications and serves as a tool for batch-level quality control.
Gepotidacin CoA mostly includes findings from lab analyses of a specific batch. For each Gepotidacin CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Gepotidacin may be tested according to a variety of international standards, such as European Pharmacopoeia (Gepotidacin EP), Gepotidacin JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Gepotidacin USP).